Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Carvedilol inhibits EGF-mediated JB6 P+ colony formation through a mechanism independent of adrenoceptors.

Cleveland KH, Liang S, Chang A, Huang KM, Chen S, Guo L, Huang Y, Andresen BT.

PLoS One. 2019 May 20;14(5):e0217038. doi: 10.1371/journal.pone.0217038. eCollection 2019.

2.

Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention.

Cleveland KH, Yeung S, Huang KM, Liang S, Andresen BT, Huang Y.

Mol Carcinog. 2018 Aug;57(8):997-1007. doi: 10.1002/mc.22820. Epub 2018 Apr 24.

PMID:
29626349
3.

Topically Applied Carvedilol Attenuates Solar Ultraviolet Radiation Induced Skin Carcinogenesis.

Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL Jr, Andresen BT, Huang Y.

Cancer Prev Res (Phila). 2017 Oct;10(10):598-606. doi: 10.1158/1940-6207.CAPR-17-0132. Epub 2017 Aug 15.

4.

Heat acclimation and thirst in rats.

Barney CC, Schanhals EM, Grobe JL, Andresen BT, Traver M.

Physiol Rep. 2015 Dec;3(12). pii: e12642. doi: 10.14814/phy2.12642.

5.

The basis of translational physiology: from molecules to humans, a wide arc of scientific inquiry.

Andresen BT.

Physiology (Bethesda). 2015 Jan;30(1):4-5. doi: 10.1152/physiol.00055.2014. Review. No abstract available.

6.

Prevention of skin carcinogenesis by the β-blocker carvedilol.

Chang A, Yeung S, Thakkar A, Huang KM, Liu MM, Kanassatega RS, Parsa C, Orlando R, Jackson EK, Andresen BT, Huang Y.

Cancer Prev Res (Phila). 2015 Jan;8(1):27-36. doi: 10.1158/1940-6207.CAPR-14-0193. Epub 2014 Nov 3.

7.

The β-blocker Nebivolol Is a GRK/β-arrestin biased agonist.

Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L, Bastepe M, Jackson EK, Andresen BT.

PLoS One. 2013 Aug 20;8(8):e71980. doi: 10.1371/journal.pone.0071980. eCollection 2013.

8.

Angiotensin type 1 receptor resistance to blockade in the opossum proximal tubule cell due to variations in the binding pocket.

Nistala R, Andresen BT, Pulakat L, Meuth A, Sinak C, Mandavia C, Thekkumkara T, Speth RC, Whaley-Connell A, Sowers JR.

Am J Physiol Renal Physiol. 2013 Apr 15;304(8):F1105-13. doi: 10.1152/ajprenal.00127.2012. Epub 2013 Feb 6.

9.

Aquaporin-2 levels in vitro and in vivo are regulated by VACM-1, a cul 5 gene.

Le IP, Schultz S, Andresen BT, Dewey GL, Zhao P, Listenberger L, Deen PM, Buchwalter A, Barney CC, Burnatowska-Hledin MA.

Cell Physiol Biochem. 2012;30(5):1148-58. doi: 10.1159/000343305. Epub 2012 Oct 5.

10.

VACM-1/cul5 expression in vascular tissue in vivo is induced by water deprivation and its expression in vitro regulates aquaporin-1 concentrations.

Johnson AE, Le IP, Andresen BT, Stodola J, Dewey GL, Dean SB, Resau J, Haak P, Ruch T, Sartor A, Lazdins I, Barney CC, Burnatowska-Hledin MA.

Cell Tissue Res. 2012 Aug;349(2):527-39. doi: 10.1007/s00441-012-1419-3. Epub 2012 May 13.

PMID:
22581383
11.

Brave new world? Arrestin pathway bias in drug design.

Andresen BT, Luttrell LM.

Endocr Metab Immune Disord Drug Targets. 2011 Jun;11(2):90-1. No abstract available.

PMID:
21599621
12.

A pharmacological primer of biased agonism.

Andresen BT.

Endocr Metab Immune Disord Drug Targets. 2011 Jun;11(2):92-8. Review.

13.

Inflammation and reactive oxygen species in cardiovascular disease.

Zhang N, Andresen BT, Zhang C.

World J Cardiol. 2010 Dec 26;2(12):408-10. doi: 10.4330/wjc.v2.i12.408.

14.

Characterization of G protein-coupled receptor kinase 4 and measuring its constitutive activity in vivo.

Andresen BT.

Methods Enzymol. 2010;484:631-51. doi: 10.1016/B978-0-12-381298-8.00031-9.

PMID:
21036254
15.

Association of vascular endothelial growth factor -634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese.

Yang Y, Andresen BT, Yang K, Zhang Y, Li X, Li X, Wang H.

Exp Biol Med (Maywood). 2010 Oct;235(10):1204-11. doi: 10.1258/ebm.2010.010102. Epub 2010 Aug 26.

PMID:
20801867
16.

Slower decline of renal function after initiation of rosiglitazone in diabetics -- a pilot study.

Trivedi H, Lu N, Andresen BT, Whaley-Connell A.

Clin Nephrol. 2009 Sep;72(3):181-5.

PMID:
19761722
17.

Renal and vascular benefits of C-peptide: Molecular mechanisms of C-peptide action.

Nordquist L, Palm F, Andresen BT.

Biologics. 2008 Sep;2(3):441-52.

18.

Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat.

DeMarco VG, Habibi J, Whaley-Connell AT, Schneider RI, Sowers JR, Andresen BT, Gutweiler AA, Ma L, Johnson MS, Ferrario CM, Dellsperger KC.

Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1128-39. doi: 10.1152/ajpheart.00048.2009. Epub 2009 Jul 24.

19.

Comparison of inhibitors of superoxide generation in vascular smooth muscle cells.

Luo Z, Chen Y, Chen S, Welch WJ, Andresen BT, Jose PA, Wilcox CS.

Br J Pharmacol. 2009 Jul;157(6):935-43. doi: 10.1111/j.1476-5381.2009.00259.x. Epub 2009 May 18.

20.

Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat.

DeMarco VG, Habibi J, Whaley-Connell AT, Schneider RI, Heller RL, Bosanquet JP, Hayden MR, Delcour K, Cooper SA, Andresen BT, Sowers JR, Dellsperger KC.

Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2659-68. doi: 10.1152/ajpheart.00953.2007. Epub 2008 Apr 18.

21.

G protein-coupled receptor kinase 4gamma interacts with inactive Galpha(s) and Galpha13.

Keever LB, Jones JE, Andresen BT.

Biochem Biophys Res Commun. 2008 Mar 14;367(3):649-55. doi: 10.1016/j.bbrc.2007.12.181. Epub 2008 Jan 9.

22.

Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.

Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, Rehmer N, DeMarco VG, Andresen BT, Wei Y, Ferrario C, Sowers JR.

Hypertension. 2008 Feb;51(2):474-80. doi: 10.1161/HYPERTENSIONAHA.107.102467. Epub 2008 Jan 2.

23.
24.

Enhanced activation of RhoA by angiotensin II in SHR preglomerular microvascular smooth muscle cells.

Jackson EK, Andresen BT, Seasholtz TM, Zhu C, Romero GG.

J Cardiovasc Pharmacol. 2005 Apr;45(4):283-5.

PMID:
15772513
25.

AT2 receptors cross talk with AT1 receptors through a nitric oxide- and RhoA-dependent mechanism resulting in decreased phospholipase D activity.

Andresen BT, Shome K, Jackson EK, Romero GG.

Am J Physiol Renal Physiol. 2005 Apr;288(4):F763-70. Epub 2004 Nov 30.

26.

AT2 receptors attenuate AT1 receptor-induced phospholipase D activation in vascular smooth muscle cells.

Andresen BT, Romero GG, Jackson EK.

J Pharmacol Exp Ther. 2004 Apr;309(1):425-31. Epub 2004 Jan 13.

PMID:
14722318
27.

Role of EGFR transactivation in angiotensin II signaling to extracellular regulated kinase in preglomerular smooth muscle cells.

Andresen BT, Linnoila JJ, Jackson EK, Romero GG.

Hypertension. 2003 Mar;41(3 Pt 2):781-6. Epub 2003 Jan 6.

PMID:
12623996
28.

The role of phosphatidic acid in the regulation of the Ras/MEK/Erk signaling cascade.

Andresen BT, Rizzo MA, Shome K, Romero G.

FEBS Lett. 2002 Oct 30;531(1):65-8. Review.

29.

Angiotensin II signaling to phospholipase D in renal microvascular smooth muscle cells in SHR.

Andresen BT, Jackson EK, Romero GG.

Hypertension. 2001 Feb;37(2 Pt 2):635-9.

PMID:
11230348
30.

Role of adenosine A(1) receptors in modulating extracellular adenosine levels.

Andresen BT, Gillespie DG, Mi Z, Dubey RK, Jackson EK.

J Pharmacol Exp Ther. 1999 Oct;291(1):76-80.

PMID:
10490889

Supplemental Content

Loading ...
Support Center